Steven Holtzman joined Decibel Therapeutics as president and chief executive officer in 2016. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc., where he led eight new drug approvals. Previously, he was the founder, chief executive officer, and board chair of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in large-scale genetics and genomics, and a founder, board member, and executive vice president of DNX Corporation, the first transgenic animal company.
Holtzman is chairman of the boards of Qihan Biotech and CAMP4 Therapeutics, a board member of Molecular Partners, a strategic business advisor to Humatics and Compugen, a member of the board of Berklee College of Music, and a senior fellow at the Belfer Center for Science and International Affairs at the Harvard Kennedy School. He was appointed by President Bill Clinton to the National Bioethics Advisory Commission and also served as a member and vice chair of the board of the Hastings Center for the Life Sciences. He obtained his undergraduate degree in philosophy from Michigan State University and his graduate degree in philosophy from Oxford University, which he attended as a Rhodes Scholar.